Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)DivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Share-based Compensation (2019 - 2025)

BridgeBio Pharma (BBIO) has disclosed Share-based Compensation for 7 consecutive years, with $34.6 million as the latest value for Q4 2025.

  • Quarterly Share-based Compensation rose 14.98% to $34.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $129.5 million through Dec 2025, up 20.41% year-over-year, with the annual reading at $133.0 million for FY2025, 38.86% up from the prior year.
  • Share-based Compensation hit $34.6 million in Q4 2025 for BridgeBio Pharma, up from $31.7 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $37.3 million in Q2 2025 to a low of $16.1 million in Q3 2021.
  • Historically, Share-based Compensation has averaged $27.5 million across 5 years, with a median of $27.2 million in 2023.
  • Biggest five-year swings in Share-based Compensation: surged 228.48% in 2021 and later fell 28.16% in 2022.
  • Year by year, Share-based Compensation stood at $22.5 million in 2021, then rose by 6.86% to $24.1 million in 2022, then surged by 53.9% to $37.0 million in 2023, then dropped by 18.63% to $30.1 million in 2024, then increased by 14.98% to $34.6 million in 2025.
  • Business Quant data shows Share-based Compensation for BBIO at $34.6 million in Q4 2025, $31.7 million in Q3 2025, and $37.3 million in Q2 2025.